ASCO24 Updates: Innovative 177Lu-PSMA-617 Therapy: Enhanced Survival in Prostate Cancer

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Scott T. Tagawa, MD, MS, Medical Oncologist at NewYork-Presbyterian – Weill Cornell Medical Center and Professor of Medicine and Urology at Weill Cornell Medicine, shares insights about their poster on “Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).”

More videos and content from ASCO 2024 on OncoDaily.